1. Protein Tyrosine Kinase/RTK
  2. Btk

Btk

Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.

Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.

Btk Related Products (27):

Cat. No. Product Name Effect Purity
  • HY-10997
    PCI-32765 Inhibitor 99.87%
    PCI-32765 is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
  • HY-17600
    Acalabrutinib Inhibitor 98.74%
    Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK (Bruton's tyrosine kinase) that has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases, such as EGFR,TEC, and ITK.
  • HY-19834
    GDC-0853 Inhibitor 99.42%
    GDC-0853 is a potent and orally BTK inhibitor.
  • HY-18012
    AVL-292 Inhibitor 99.95%
    AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM; >1400-fold selectivity over the other kinases assayed.
  • HY-15427
    GDC-0834 Inhibitor 98.02%
    GDC-0834 is a potent and selective BTK inhibitor.
  • HY-101941
    SNS-062 Inhibitor 98.88%
    SNS-062 is a potent, noncovalent BTK and ITK inhibitor, with Kd of 0.3 nM and 2.2 nM, respectively; with IC50 of 24 nM for ITK.
  • HY-80002
    BMX-IN-1 Inhibitor 98.88%
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
  • HY-15771
    ONO-4059 Inhibitor 98.31%
    ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
  • HY-101215
    Evobrutinib Inhibitor 98.17%
    Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174.
  • HY-18951
    ONO-4059 analog Inhibitor 99.62%
    The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range.
  • HY-18018
    RN486 Inhibitor 99.38%
    RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
  • HY-18009
    LFM-A13 Inhibitor 99.47%
    LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
  • HY-10997A
    PCI-32765 Racemate Inhibitor
    PCI-32765 Racemate is the racemate of PCI-32765.
  • HY-80003
    QL47 Inhibitor
    QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
  • HY-15427A
    GDC-0834 Racemate
    GDC-0834 Racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
  • HY-101474
    BGB-3111 Inhibitor 99.70%
    BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
  • HY-11999
    CGI-1746 Inhibitor
    CGI-1746 is a small-molecule Bruton's tyrosine kinase (Btk) inhibitor.
  • HY-100342
    Ibrutinib-biotin Inhibitor 99.67%
    Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK.
  • HY-18010
    PCI 29732 Inhibitor
    PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
  • HY-15771A
    ONO-4059 hydrochloride Inhibitor 98.74%
    ONO-4059 is a selective and novel inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.